Jonathan Mizrahi, MD
The standard of care for patients with metastatic colorectal cancer (mCRC) can continued to be improved through better use of molecular testing, explained Jonathan Mizrahi, MD.
As more molecular subsets are defined, and additional targeted therapies are developed, the importance of understanding the underlying genomic makeup of a patient’s tumor is becoming increasingly important.
Two examples of this research focus were presented at the 2019 Gastrointestinal Cancers Symposium, both of which confirmed the benefit of targeted therapy for patients with identifiable genomic abnormalities, such as BRAF
V600E–mutant and microsatellite stable (MSS) disease. Updated results from the safety lead-in portion of the phase III BEACON CRC trial showed that the combination of encorafenib (Braftovi), binimetinib (Mektovi), and cetuximab (Erbitux) induced a high objective response rate (ORR) of 48% in patients with BRAF
V600E–mutant mCRC by local assessment, surpassing historical ORRs of <10%.1
... to read the full story